Join the Elahere group to help and get support from people like you.
Elahere News
U.S. Food and Drug Administration (FDA) Grants Full Approval for Elahere (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
The full approval of Elahere is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, ...
Mirvetuximab Soravtansine-Gynx Beneficial for FRα-Positive Ovarian Cancer
THURSDAY, Dec. 7, 2023 – For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a...
FDA Approves Elahere (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
Elahere is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin® Use ...
Ask a question
To post your own question to this support group, sign in or create an account.